17
Participants
Start Date
August 31, 2005
Primary Completion Date
July 31, 2006
Study Completion Date
January 31, 2009
Systematic chemotherapy and antibodies
"Systemic chemotherapy and antibodies as follows:~Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD"
Allogeneic stem cell transplantation
An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
Miltenyi CliniMACS
Miltenyi Biotec CliniMACS stem cell selection device
St. Jude Children's Research Hospital, Memphis
St. Jude Children's Research Hospital
OTHER